Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Single-arm CTL019 in Pediatric Relapsed/Refractory B-cell ALL (Japan)
jRCT2080222980Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2015
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
01
Overview
Phase 2, open-label, single-arm trial of tisagenlecleucel in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Novartis. Started Oct 2015; status: completed.
02
Drugs
tisagenlecleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on jRCT2080222980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222980.